Compare BGSI & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGSI | ZLAB |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | 2025 | 2017 |
| Metric | BGSI | ZLAB |
|---|---|---|
| Price | $76.91 | $25.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 12 |
| Target Price | ★ $148.46 | $33.14 |
| AVG Volume (30 Days) | 41.5K | ★ 708.4K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.57% | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | $29.71 | N/A |
| Revenue Next Year | $8.40 | $26.50 |
| P/E Ratio | $231.07 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $76.88 | $15.96 |
| 52 Week High | $183.10 | $33.97 |
| Indicator | BGSI | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 35.32 | 52.49 |
| Support Level | N/A | $24.81 |
| Resistance Level | $91.90 | $27.20 |
| Average True Range (ATR) | 2.61 | 0.94 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 9.11 | 46.26 |
Boyd Group Services Inc is engaged in operating non-franchised collision repair centers in North America. The Company's primary line of business is automotive collision and glass repair and related services, with the majority of revenues relating to this group of similar services. This line of business operates in Canada and the U.S. and both regions exhibit similar long-term economic characteristics. The Company is also a retail auto glass operator in the United States, under the trade names Gerber Collision & Glass, Glass America, Auto Glass Service, Auto Glass Authority. The company has majority of its sales from USA.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.